What now in HCV? Video and white paper
This article was originally published in Scrip
The euphoria-inducing near-100% cure rates seen with the new wave of hepatitis C therapies at the European Association for the Study of the Liver (EASL) International Liver Congress in London from 9-13 April have been a highlight of the year, and, some would say, the decade so far. But will the devil be in the detail, and how will the market play out when there are several companies all limbering up to launch highly effective treatments following Gilead Sciences' early lead with Sovaldi (sofosbuvir)?
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.